|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.79 EUR | +0.85% |
|
+2.74% | +6.67% |
| 02-04 | PHILIPS NV : Buy rating from Barclays | ZD |
| 02-03 | Preciseonco research consortium awarded EUR 14.9 million grant in precision cancer treatment | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Advanced Medical Equipment & Technology
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 27.85B | |||||
| 204B | |||||
| 173B | |||||
| 153B | |||||
| 113B | |||||
| 54.57B |
- Stock Market
- Equities
- PHIA Stock
- Charts Philips NV
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition